PharmAust Limited (PAA.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEST
| Previous close | 0.1950 |
| Open | 0.1950 |
| Bid | 0.2000 x 0 |
| Ask | 0.2050 x 0 |
| Day's range | 0.1950 - 0.2000 |
| 52-week range | 0.0670 - 0.5350 |
| Volume | |
| Avg. volume | 1,329,776 |
| Market cap | 99.655M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 28 July 2024 - 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.PharmAust (ASX:PAA) shareholders have earned a 21% CAGR over the last five years
While PharmAust Limited ( ASX:PAA ) shareholders are probably generally happy, the stock hasn't had particularly good...
PR NewswirePharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company"), a clinical-stage biotechnology company, is pleased to announce that it has met its primary safety and tolerability endpoints with monepantel (MPL) and, importantly, demonstrated a positive signal of potential efficacy. Rates of disease progression in patients with Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) measured by changes in ALSFRS-R may be slowed by 58% for Cohort 2, when compared to an external cont
- Simply Wall St.
PharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week alone
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
© 2024 Yahoo. All rights reserved.